Effect of cognitive enhancement therapy for early course schizophrenia on gray matter volume: A confirmatory multisite randomized clinical trial.

J Psychiatr ResAug 10, 2026 (epub)
Clinical ResearchPsychiatry

Jessica A Wojtalik, Mary L Phillips, Deepak K Sarpal et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial investigated the effects of Cognitive Enhancement Therapy (CET) on gray matter volume in 99 participants with early course schizophrenia. The study found that only the right rostral anterior cingulate showed a significant group-by-time interaction, but this change did not correlate with improvements in cognitive or social adjustment.

Key findings

  • Only the right rostral anterior cingulate showed a significant group-by-time interaction.
  • No secondary regions of interest exhibited a differential treatment effect.
  • CET did not replicate the previously observed neuroprotective effects on gray matter volume.

Why it matters

Understanding the neuroprotective effects of cognitive interventions like CET is crucial for optimizing treatment strategies in early course schizophrenia, particularly as cognitive remediation continues to evolve.

Source

PubMed · PMID 42623965

Published in J Psychiatr Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.